TuHURA Biosciences Gets Nasdaq Bid Price Notice

TuHURA Biosciences, Inc. received a notice from Nasdaq that its common stock no longer meets the minimum bid price requirement because the consolidated closing bid has been below $1.00 per share for 35 consecutive business days as of January 28, 2026.

Rhea-AI Filing Summary

TuHURA Biosciences, Inc. received a notice from Nasdaq that its common stock no longer meets the minimum bid price requirement because the consolidated closing bid has been below $1.00 per share for 35 consecutive business days as of January 28, 2026. The stock is not being immediately delisted, and the company has a 180-day grace period, until July 28, 2026, to regain compliance by maintaining a closing bid of at least $1.00 for at least ten consecutive business days. If it still fails to comply, TuHURA may be eligible for a second 180-day period, potentially including measures such as a reverse stock split, and could also request a hearing to delay any suspension or delisting. The company states that the notice does not affect its business, operations, or SEC reporting, but it cautions that there is no assurance it will regain or maintain Nasdaq listing compliance.

Positive

• None.

Negative

• Nasdaq minimum bid price noncompliance and delisting risk: TuHURA’s stock traded below $1.00 for 35 consecutive business days as of January 28, 2026, triggering a Nasdaq deficiency notice and initiating a defined timeline that could ultimately lead to delisting if compliance is not restored.

Insights

Equity & Listing Standards Analyst

Nasdaq bid-price noncompliance raises delisting risk for TuHURA.

TuHURA Biosciences has fallen below Nasdaq’s $1.00 minimum bid price for 35 consecutive business days as of January 28, 2026. This formally places the stock out of compliance with Nasdaq Listing Rule 5550(a)(2), triggering a structured remediation timeline.

The company now has a 180-day grace period, until July 28, 2026, to achieve a closing bid of at least $1.00 for ten consecutive business days. Failing that, a second 180-day period is possible if it meets all other initial listing standards and indicates an intention to cure, potentially via a reverse stock split.

If compliance is not regained and no satisfactory plan is accepted, the common stock would be subject to delisting, though TuHURA could request a hearing before an independent Nasdaq panel to temporarily stay suspension or delisting. The company emphasizes that its operations and SEC reporting continue unchanged, but it acknowledges there is no assurance of regaining compliance.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did TuHURA Biosciences (HURA) receive a Nasdaq deficiency notice?

TuHURA Biosciences received a Nasdaq deficiency notice because its consolidated closing bid price stayed below $1.00 per share for 35 consecutive business days as of January 28, 2026. This violates Nasdaq Listing Rule 5550(a)(2) on minimum bid price requirements.

What deadline does TuHURA Biosciences (HURA) have to regain Nasdaq compliance?

TuHURA has until July 28, 2026 to regain Nasdaq compliance. It must achieve a consolidated closing bid price of at least $1.00 per share for a minimum of ten consecutive business days within this 180-day grace period.

Can TuHURA Biosciences (HURA) get more time beyond the first 180-day period?

Yes. If TuHURA is still noncompliant on July 28, 2026, it may receive a second 180-day compliance period. To qualify, it must meet all other initial Nasdaq Capital Market listing standards and indicate plans to cure the bid price deficiency, potentially via a reverse stock split.

Is TuHURA Biosciences (HURA) being immediately delisted from Nasdaq?

No. The notice does not cause immediate delisting from The Nasdaq Capital Market. TuHURA retains a 180-day grace period, and potentially a second 180-day period and a hearing opportunity, before any suspension or delisting could occur under Nasdaq procedures.

Does the Nasdaq notice affect TuHURA Biosciences’ business operations?

The company states that receiving the Nasdaq notice does not affect its current business, operations, or SEC reporting obligations. The issue relates specifically to compliance with Nasdaq’s minimum bid price listing standard, not to ongoing operational activities.

What actions might TuHURA Biosciences (HURA) take to fix its Nasdaq bid price issue?

TuHURA notes it will monitor its closing bid price and consider available options. If granted a second compliance period, it would be required to notify Nasdaq of its intention to cure the deficiency, which may include effecting a reverse stock split if necessary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/30/2026 - 04:00 PM Learn about SEC filing dates

0001498382falseTuHURA BIOSCIENCES, INC./NV00014983822026-01-292026-01-29

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 29, 2026

TUHURA BIOSCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)

Nevada		001-37823		99-0360497
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
10500 University Center Dr., Suite 110
Tampa, Florida 33612
(Address of Principal Executive Offices, including zip code)
Registrant’s Telephone Number, Including Area Code: (813) 875-6600

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		HURA		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On January 29, 2026, TuHURA Biosciences, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s consolidated closing bid price has been below $1.00 per share for 35 consecutive business days as of January 28, 2026, and that, therefore, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which is the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market.

Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has automatically been afforded a 180-calendar day grace period, or until July 28, 2026, to regain compliance. The continued listing standard will be met if the consolidated closing bid price of the Company’s common stock is at least $1.00 per share for a minimum of ten consecutive business days during the 180-calendar day grace period.

If the Company is not in compliance by July 28, 2026, the Company may be afforded a second 180-calendar day period to regain compliance. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except for the minimum bid price requirement. In addition, the Company would be required to notify Nasdaq of its intention to cure the minimum bid price deficiency during the second compliance period by effecting a reverse stock split, if necessary.

If the Company does not regain compliance within the allotted 180-day compliance period and is not eligible for a second 180-day compliance period, the Company’s common stock would be subject to delisting unless it requested a hearing before an independent Nasdaq Hearings Panel. A request for a hearing would stay any suspension or delisting action pending the hearing and any additional extension period granted by the Nasdaq Hearings Panel.

The Company intends to monitor the closing bid price of the Company’s common stock and consider its available options to resolve the non-compliance with the minimum bid price requirement. The Company’s receipt of the notice does not affect the Company’s business, operations or reporting requirements with the Securities and Exchange Commission. However, there can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with other Nasdaq listing criteria.

Forward-Looking Statements

This Current Report on Form 8-K may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainty. Words such as “anticipate,” “estimate,” “expect,” “intend,” “plan,” and “project” and other similar words and expressions are intended to signify forward-looking statements. Forward-looking statements are not guarantees of future results and conditions but rather are subject to various risks and uncertainties. Such statements are based on the Company’s current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Investors are cautioned that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various risks and uncertainties. Investors should refer to the risks detailed from time to time in the reports the Company files with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other filings on Form 10-Q and periodic filings on Form 8-K, for additional factors that could cause actual results to differ materially from those stated or implied by such forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			TUHURA BIOSCIENCES, INC.
Date:	January 30, 2026	By:	/s/ Dan Dearborn
			Name: Dan Dearborn Title: Chief Financial Officer